P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY

• Nicholas Short,
• Elias Jabbour,
• Nitin Jain,
• Fadi Haddad,
• Musa Yilmaz,
• Lewis Nasr,
• Alessandra Ferrajoli,
• Tapan Kadia,
• Yesid Alvarado,
• Abhishek Maiti,
• Walid Macaron,
• Marianne Zoghbi,
• Cedric Nasnas,
• Rebecca Garris,
• Min Zhao,
• Marina Konopleva,
• Farhad Ravandi,
• Hagop Kantarjian

Affiliations

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Elias Jabbour

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Nitin Jain

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Fadi Haddad

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Musa Yilmaz

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Lewis Nasr

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Alessandra Ferrajoli

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Tapan Kadia

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Yesid Alvarado

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Abhishek Maiti

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Walid Macaron

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Marianne Zoghbi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Cedric Nasnas

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Rebecca Garris

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Min Zhao

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Marina Konopleva

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States